FDA approves RYBREVANT and LAZCLUZE for EGFR-mutated advanced lung cancer
The U.S. Food and Drug Administration (FDA) has approved the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a first-line therapy for adults with advanced non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) mutations. This approval marks a significant advancement in the treatment landscape for patients with EGFR-mutated NSCLC, providing a […]